Skip to main content
Caplight Logo









Amber Therapeutics

Amber Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.amber-tx.com/

Last Round

Series A

Jun 10, 2024

Total Funding Raised

$100M

Company Overview

Amber Therapeutics is a biotechnology company that develops innovative bioelectronic platforms for closed-loop therapies aimed at treating mixed urinary incontinence through targeted peripheral interventions.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Keywords

neuromodulationimplantable medical devicebio-electronic therapyurinary incontinenceclosed-loop neuromodulationadaptive stimulationmedtechclinical-stage biotechurology devicesmart implantbioelectronicsmedical devicedigital health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Amber Therapeutics Comparables

Compare Amber Therapeutics with similar companies based on industry and business-model similarity.

Amber Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Juniper Biomedical
85%
BlueWind Medical
83%
Neuspera Medical
80%

Amber Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 10, 2024
SeedJan 24, 2023

Key People

Founding team and executive leadership

Aidan Crawley

Co-Founder, CEO

Founding Team

Amber Therapeutics Investors

Notable investors and investment history

Amber Therapeutics investors
InvestorRounds
New Enterprise Associates (NEA)Series A
Lightstone VenturesSeries A
Oxford Science EnterprisesSeries A, Seed
F-Prime CapitalSeries A
UKRI Innovate UKSeed
Intuitive VenturesSeries A
Oxford Science EnterprisesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2025

    Accelerating towards first Pivotal Trial for Picostim System.

  • Jun 10, 2024

    $100M round led by New Enterprise Associates (NEA)

Amber Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Amber Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Amber Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range61
Year Founded2021
Last FundingJun 10, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?